BLR-100 / BLR Bio - LARVOL DELTA

Promising New Data Published on Potential Therapy to Boost Effectiveness of Pancreatic Cancer Treatments (PRNewswire) - "BLR Bio...released new data on its novel cancer therapy recently at the 7^th annual Labroots Drug Discovery and Development conference. The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers...The current study...demonstrates that the use of BLR's compound — BLR-100 — could provide similar efficacy to a doubling of the dose of existing chemotherapy without increasing side effects of these therapeutics, which often impact patient quality of life during treatment....BLR-100 is also expected to allow better access to normal immune clearance mechanisms as well as the new immuno-oncology drugs, which to date have not been effective in cancers like PNAC. BLR Bio is currently completing IND-enabling studies for this novel compound."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor